Eric Vernier
Neurology with Special Qualifications in Child Neurology · Tampa, FLNPI 1174755110
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Eisai Inc. at 37.2% of the total. Reporting peaked in 2019 at $10,111 and has fallen 68.5% since, to $3,183 in 2025.
Across 1,162 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$12K
- Neurelis, Inc.$7K
- UCB, Inc.$4K
- Ironshore Pharmaceuticals Inc.$1K
- Jazz Pharmaceuticals Inc.$1K
- Supernus Pharmaceuticals, Inc.$1K
- plus $6K from 28 others
What the payments were for
- Consulting fees$4501%
- Speaking & faculty fees$16,33349%
- Travel & lodging$40%
- Food & beverage$16,52750%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 70 | $12,410 |
| Neurelis, Inc. | 94 | $7,408 |
| UCB, Inc. | 179 | $3,558 |
| Ironshore Pharmaceuticals Inc. | 224 | $1,441 |
| Jazz Pharmaceuticals Inc. | 57 | $1,255 |
| Supernus Pharmaceuticals, Inc. | 170 | $1,113 |
| Corium, LLC | 50 | $960 |
| Sunovion Pharmaceuticals Inc. | 45 | $688 |
| Tris Pharma Inc | 32 | $529 |
| Aquestive Therapeutics, Inc. | 27 | $455 |
| Livanova USA, Inc. | 11 | $443 |
| Acadia Pharmaceuticals Inc | 18 | $437 |
| Catalyst Pharmaceuticals, Inc. | 25 | $412 |
| Collegium Pharmaceutical, Inc. | 64 | $294 |
| Sumitomo Pharma America, Inc. | 15 | $287 |
| Greenwich Biosciences, Inc. | 9 | $245 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $241 |
| SK Life Science, Inc. | 8 | $195 |
| AbbVie(2 entities) | 5 | $115 |
| Noven Therapeutics, LLC | 6 | $114 |
| Immedica Pharma US, Inc. | 3 | $98 |
| Neos Therapeutics, LP | 5 | $90 |
| Aucta Pharmaceuticals, Inc. | 9 | $80 |
| Zogenix Inc. | 4 | $79 |
| Biogen | 4 | $73 |
| NS Pharma, Inc. | 4 | $73 |
| Otter Pharmaceuticals, LLC | 2 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Cranial Technologies, Inc | 2 | $29 |
| Upsher-smith Laboratories LLC | 1 | $29 |
| Biocodex, Inc. | 1 | $28 |
| Noven Pharmaceuticals, Inc. | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$11,486
- VALTOCO$5,663
- Epidiolex$247
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$135
- SYMPAZAN$124
- APTIOM$120
- Jornay PM 20mg capsules (Bottle of 100)$104
- QELBREE$100
How this compares
$33,333 in reported general payments places this provider in the 85th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 15 | $282,579 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,533 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,706 |
| Clonazepam | 29 | $1,729 |
| Mirtazapine | 16 | $196 |
| Montelukast Sodium | 16 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla | $3,558 | $282,57915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
Other neurology with special qualifications in child neurology in Tampa
- Jose FerreiraTampa$88K
- Anne CsereTampa$29K
- Sergio JacintoTampa$21K
- Jose ForadadaTampa$13K
- Ernesto MillanTampa$11K
- Sagarika NalluTampa$7K
- Paul WinnerWest Palm Beach$624K
- Omer Abdul HamidOrlando$283K
- Natalie GillsonFort Myers$250K
- Trevor ResnickMiami$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.